Jeffrey S. Parkin

Array ( [id] => 6135216 [patent_doc_number] => 20110008889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-13 [patent_title] => 'SERPIN DRUGS FOR TREATMENT OF HIV INFECTION AND METHOD OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/391669 [patent_app_country] => US [patent_app_date] => 2009-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 16950 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0008/20110008889.pdf [firstpage_image] =>[orig_patent_app_number] => 12391669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5545897 [patent_doc_number] => 20090155774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-06-18 [patent_title] => 'Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell' [patent_app_type] => utility [patent_app_number] => 12/378572 [patent_app_country] => US [patent_app_date] => 2009-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 15596 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0155/20090155774.pdf [firstpage_image] =>[orig_patent_app_number] => 12378572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6212908 [patent_doc_number] => 20110136208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-09 [patent_title] => 'ANTIGEN-SPECIFIC REGULATORY T-CELL INDUCTION' [patent_app_type] => utility [patent_app_number] => 12/867703 [patent_app_country] => US [patent_app_date] => 2009-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11863 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0136/20110136208.pdf [firstpage_image] =>[orig_patent_app_number] => 12867703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5391217 [patent_doc_number] => 20090208530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-20 [patent_title] => 'HIV polynucleotides and polypeptides derived from Botswana MJ4' [patent_app_type] => utility [patent_app_number] => 12/365215 [patent_app_country] => US [patent_app_date] => 2009-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 24747 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0208/20090208530.pdf [firstpage_image] =>[orig_patent_app_number] => 12365215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5397356 [patent_doc_number] => 20090317419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-24 [patent_title] => 'Tetramers' [patent_app_type] => utility [patent_app_number] => 12/320709 [patent_app_country] => US [patent_app_date] => 2009-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 18748 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0317/20090317419.pdf [firstpage_image] =>[orig_patent_app_number] => 12320709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7795396 [patent_doc_number] => 08124102 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-02-28 [patent_title] => 'Method for the reduction of viral loads in patients comprising the administration of nef-deficient human immunodeficiency virus (HIV)' [patent_app_type] => utility [patent_app_number] => 12/321456 [patent_app_country] => US [patent_app_date] => 2009-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4871 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/124/08124102.pdf [firstpage_image] =>[orig_patent_app_number] => 12321456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5558911 [patent_doc_number] => 20090270488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-10-29 [patent_title] => 'Process for the Selection of HIV-1 Subtype C Isolates, Selected HIV-1 Subtype Isolates, Their Genes and Modifications and Derivatives Thereof' [patent_app_type] => utility [patent_app_number] => 12/357099 [patent_app_country] => US [patent_app_date] => 2009-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 9893 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0270/20090270488.pdf [firstpage_image] =>[orig_patent_app_number] => 12357099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6295414 [patent_doc_number] => 20100160262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-24 [patent_title] => 'COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY' [patent_app_type] => utility [patent_app_number] => 12/343177 [patent_app_country] => US [patent_app_date] => 2008-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 29785 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0160/20100160262.pdf [firstpage_image] =>[orig_patent_app_number] => 12343177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6087989 [patent_doc_number] => 20110217328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-08 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION' [patent_app_type] => utility [patent_app_number] => 12/809370 [patent_app_country] => US [patent_app_date] => 2008-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7249 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0217/20110217328.pdf [firstpage_image] =>[orig_patent_app_number] => 12809370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6616156 [patent_doc_number] => 20100310592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-09 [patent_title] => 'A TRUNCATED FORM OF THE HIV P17 PROTEIN' [patent_app_type] => utility [patent_app_number] => 12/812747 [patent_app_country] => US [patent_app_date] => 2008-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6287 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0310/20100310592.pdf [firstpage_image] =>[orig_patent_app_number] => 12812747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 130803 [patent_doc_number] => 07700116 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-04-20 [patent_title] => 'Method of inducing an immune response in a host by administering immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane' [patent_app_type] => utility [patent_app_number] => 12/315776 [patent_app_country] => US [patent_app_date] => 2008-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10867 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/700/07700116.pdf [firstpage_image] =>[orig_patent_app_number] => 12315776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 173553 [patent_doc_number] => 07658932 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-02-09 [patent_title] => 'Method of making immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane' [patent_app_type] => utility [patent_app_number] => 12/315777 [patent_app_country] => US [patent_app_date] => 2008-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10863 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/658/07658932.pdf [firstpage_image] =>[orig_patent_app_number] => 12315777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6518129 [patent_doc_number] => 20100261751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-14 [patent_title] => 'METHOD FOR DETERMINING ONE OF THE TWO HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTEGRASE ENZYMATIC ACTIVITIES' [patent_app_type] => utility [patent_app_number] => 12/742374 [patent_app_country] => US [patent_app_date] => 2008-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2841 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0261/20100261751.pdf [firstpage_image] =>[orig_patent_app_number] => 12742374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6070145 [patent_doc_number] => 20110044995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-24 [patent_title] => 'ANTI-HIV MONOCLONAL ANTIBODY' [patent_app_type] => utility [patent_app_number] => 12/743442 [patent_app_country] => US [patent_app_date] => 2008-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10310 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0044/20110044995.pdf [firstpage_image] =>[orig_patent_app_number] => 12743442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9191027 [patent_doc_number] => 20130330342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-12 [patent_title] => 'ANTIBODY FRAGMENTS INHIBITING HIV NEF PROTEIN' [patent_app_type] => utility [patent_app_number] => 12/734773 [patent_app_country] => US [patent_app_date] => 2008-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 10926 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12734773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5354706 [patent_doc_number] => 20090186050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-07-23 [patent_title] => 'Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains' [patent_app_type] => utility [patent_app_number] => 12/292000 [patent_app_country] => US [patent_app_date] => 2008-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 51865 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0186/20090186050.pdf [firstpage_image] =>[orig_patent_app_number] => 12292000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5953132 [patent_doc_number] => 20110033837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-10 [patent_title] => 'IMMORTALIZED HUMAN CD4-POSITIVE CELL AND ITS USE FOR DETERMINING THE PHENOTYPE OF A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1' [patent_app_type] => utility [patent_app_number] => 12/743073 [patent_app_country] => US [patent_app_date] => 2008-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8369 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0033/20110033837.pdf [firstpage_image] =>[orig_patent_app_number] => 12743073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5580564 [patent_doc_number] => 20090175910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-07-09 [patent_title] => 'Modifications of HIV Env, Gag, and Pol enhance immunogenicity for genetic immunization' [patent_app_type] => utility [patent_app_number] => 12/291533 [patent_app_country] => US [patent_app_date] => 2008-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 190 [patent_figures_cnt] => 190 [patent_no_of_words] => 61152 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0175/20090175910.pdf [firstpage_image] =>[orig_patent_app_number] => 12291533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6340141 [patent_doc_number] => 20100247559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-30 [patent_title] => 'WEST NILE VIRUS VACCINE, AND METHOD FOR PRODUCTION THEREOF' [patent_app_type] => utility [patent_app_number] => 12/741479 [patent_app_country] => US [patent_app_date] => 2008-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9031 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0247/20100247559.pdf [firstpage_image] =>[orig_patent_app_number] => 12741479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7739514 [patent_doc_number] => 08105600 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-01-31 [patent_title] => 'Method of inducing high-titer neutralizing antibody responses in a host by administering immune complexes comprising anti-HIV-1 Env antibodies and the HIV-1 Env' [patent_app_type] => utility [patent_app_number] => 12/261359 [patent_app_country] => US [patent_app_date] => 2008-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 16312 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/105/08105600.pdf [firstpage_image] =>[orig_patent_app_number] => 12261359 [rel_patent_id] =>[rel_patent_doc_number] =>)